Review anchor
Trifunctional purine biosynthetic protein adenosine-3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Trifunctional purine biosynthetic protein adenosine-3
CHEMBL3972
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Trifunctional purine biosynthetic protein adenosine-3 as ChEMBL target CHEMBL3972, mapped to UniProt P22102. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3972
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P22102
Trifunctional purine biosynthetic protein adenosine-3
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Trifunctional purine biosynthetic protein adenosine-3 matters
Trifunctional purine biosynthetic protein adenosine-3 is reviewed as Trifunctional purine biosynthetic protein adenosine-3 (UniProt P22102); Trifunctional purine biosynthetic protein adenosine-3 shows approved-linked disease relevance led by mesothelioma. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 189 compounds, and 112 assays, with lead potency reaching pChEMBL 10.8.
Protein context
Trifunctional purine biosynthetic protein adenosine-3
Trifunctional purine biosynthetic protein adenosine-3 Sequence length is 1010 aa.
Review this target as Trifunctional purine biosynthetic protein adenosine-3, mapped to UniProt P22102. Sequence length is 1010 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P22102
Protein
Disease context
mesothelioma
Trifunctional purine biosynthetic protein adenosine-3 shows approved-linked disease relevance led by mesothelioma. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include PEMETREXED, PEMETREXED DISODIUM, PEMETREXED MONOHYDRATE.
Start review with mesothelioma because it currently carries approved-linked support. Linked drugs include PEMETREXED, PEMETREXED DISODIUM, PEMETREXED MONOHYDRATE, PEMETREXED TROMETHAMINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
4 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 2 approved drugs, 189 compounds, and 112 assays for this target. The dominant activity type is IC50. CHEMBL279302 is the current potency anchor at pChEMBL 10.8.
Use CHEMBL279302 as the tractability anchor when discussing potency (pChEMBL 10.8).
Activity source · ChEMBL 36 via Core Engine
2 approved
pChEMBL 10.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Trifunctional purine biosynthetic protein adenosine-3 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P22102, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why mesothelioma is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
189
Total Compounds
112
Total Assays
2
Approved Drugs
IC50: 128.0, KI: 83.0, KD: 2.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL279302
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL4643623
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL4437824
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL2158681
|
9.2 | IC50 | — |
|
|
No preferred name
CHEMBL4465095
|
9.2 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
PEMETREXED
CHEMBL225072
|
2004 |
Source Header